Ticker: XBIO

Xenetic Biosciences, Inc. (NASDAQ: XBIO) Quick summary - what's happening inside * The company remains pre‑clinical, advancing its DNase oncology program and funding operations largely from legacy royalties and cash on hand. * Management says existing resources should fund operations for at least...

Xenetic Biosciences, Inc. (NASDAQ: XBIO) is a biopharmaceutical company focused on advancing innovative technologies for treating difficult cancers through its proprietary DNase technology. Key Financial Highlights (Q1 2025) Total Revenue: $593,261, a 16.1% increase from $510,817 in Q1 2024. Roy...